Compare VZLA & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VZLA | TNDM |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2013 |
| Metric | VZLA | TNDM |
|---|---|---|
| Price | $6.12 | $20.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $7.00 | ★ $24.06 |
| AVG Volume (30 Days) | ★ 7.0M | 1.2M |
| Earning Date | 12-12-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,007,001,000.00 |
| Revenue This Year | N/A | $8.59 |
| Revenue Next Year | N/A | $10.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.87 |
| 52 Week Low | $1.69 | $9.98 |
| 52 Week High | $6.16 | $37.93 |
| Indicator | VZLA | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 66.02 | 40.47 |
| Support Level | $5.71 | $20.21 |
| Resistance Level | $6.08 | $23.95 |
| Average True Range (ATR) | 0.26 | 1.11 |
| MACD | 0.01 | -0.39 |
| Stochastic Oscillator | 98.11 | 0.03 |
Vizsla Silver Corp is a junior mineral exploration and development company focused on advancing its Panuco silver-gold project located in Sinaloa, Mexico. The property contains quartz-carbonate veins with workings defining both steeply plunging and sub-horizontal ore shoots. Mineralization occurs as silver sulphides including argentite and acanthite, native gold, electrum and native silver associated with pyrite, minor galena, sphalerite and rare chalcopyrite. It has one operating segment, which is principally mineral exploration.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.